Lv4
648 积分 2023-09-07 加入
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)
5个月前
已完结
Oncogenic KRAS drives immunosuppression of colorectal cancer by impairing DDX60-mediated dsRNA accumulation and viral mimicry
6个月前
已完结
Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer
7个月前
已完结
皖公网安备34019202002308
